Szliszka et al. [29] treated TRAIL-resistant LNCaP prostate cancer cells with TRAIL and artemisinin C, then analyzed the expression of death receptors (TRAIL-R1/DR4 and TRAIL-R1/DR5) by flow cytometry and determined the activity of caspase-8 and caspase-3 by trypsin assay; they found that artemisinin C sensitized TRAIL-resistant LNCaP cells by participating in exogenous (receptor-mediated) and endogenous (mitochondrial) apoptosis pathways. The gene discussed is CASP3; the disease is prostate cancer.